Salah Mansour, PA
Physician Assistant · Adrian, MINPI 1427567569
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,759 of the $18,344 with a category attached, or 64.1%. 21 manufacturers reported payments, led by AbbVie at 32.7% of the total. 2025 is the largest year on record at $7,410, 4.7 times the $1,584 reported in 2021. Among physician assistant clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 483 payments — averaging $37.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Otsuka America Pharmaceutical, Inc.$2K
- Johnson & Johnson$2K
- Neurocrine Biosciences, Inc.$2K
- Alkermes, Inc.$1K
- E.r. Squibb & Sons, L.L.C.$996
- plus $4K from 15 others
What the payments were for
- Speaking & faculty fees$5,00027%
- Travel & lodging$1,5018%
- Food & beverage$11,75964%
- Education$840%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 74 | $5,995 |
| Otsuka America Pharmaceutical, Inc. | 123 | $2,383 |
| Johnson & Johnson | 33 | $2,356 |
| Neurocrine Biosciences, Inc. | 36 | $1,656 |
| Alkermes, Inc. | 26 | $1,049 |
| E.r. Squibb & Sons, L.L.C. | 29 | $996 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 41 | $942 |
| Axsome Therapeutics, Inc. | 19 | $712 |
| Supernus Pharmaceuticals, Inc. | 37 | $671 |
| Teva Pharmaceuticals USA, Inc. | 8 | $349 |
| Lundbeck LLC | 20 | $294 |
| Vanda Pharmaceuticals Inc. | 7 | $215 |
| Ironshore Pharmaceuticals Inc. | 4 | $161 |
| Indivior Inc. | 7 | $148 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $114 |
| Idorsia Pharmaceuticals US Inc | 1 | $113 |
| Corium, LLC | 5 | $71 |
| Sunovion Pharmaceuticals Inc. | 3 | $50 |
| Sage Therapeutics, LLC | 1 | $28 |
| Tempus AI, Inc | 1 | $24 |
| GSK | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$5,246
- SPRAVATO$1,559
- INGREZZA$1,131
- ARISTADA$1,000
- LYBALVI$934
- REXULTI$588
- COBENFY$375
- ABILIFY MAINTENA$368
- CAPLYTA$354
- Auvelity$341
- ARISTADA INITIO$250
- ABILIFY ASIMTUFII$247
- QELBREE$133
- AUSTEDO$126
- Fanapt$125
- JORNAY PM$124
- Austedo XR$120
- QUVIVIQ$113
How this compares
$18,344 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 34 | $263,425 |
| Invega SustennaPaliperidone Palmitate | 92 | $247,480 |
| RexultiBrexpiprazole | 113 | $164,810 |
| VraylarCariprazine Hcl | 99 | $155,589 |
| Abilify MaintenaAripiprazole | 35 | $98,914 |
| UzedyRisperidone | 19 | $57,854 |
| AuvelityDextromethorphan Hbr/Bupropion | 54 | $53,727 |
| CaplytaLumateperone Tosylate | 28 | $45,056 |
| AustedoDeutetrabenazine | 12 | $43,367 |
| LybalviOlanzapine/Samidorphan Malate | 22 | $36,932 |
| TrintellixVortioxetine Hydrobromide | 55 | $25,757 |
| Lurasidone Hcl | 74 | $24,621 |
| Clozapine OdtClozapine | 17 | $15,961 |
| QuviviqDaridorexant Hcl | 22 | $10,838 |
| FetzimaLevomilnacipran Hcl | 16 | $8,605 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $2,383 | $263,723148 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,656 | $263,42534 claims |
| Johnson & JohnsonInvega Sustenna | $2,356 | $247,48092 claims |
| AbbVieVraylar, Fetzima | $5,995 | $164,195115 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy, Austedo | $349 | $101,22131 claims |
| Axsome Therapeutics, Inc.Auvelity | $712 | $53,72754 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $942 | $45,05628 claims |
| Alkermes, Inc.Lybalvi | $1,049 | $36,93222 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $114 | $34,35478 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $113 | $10,83822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.
Other physician assistant in Adrian
- Taylor HennrickAdrian$430K
- Sarang PatelRoyal Oak$660K
- Beth SweneyAda$617K
- Zainab JishiCanton$596K
- Erin van DykeGrand Rapids$346K
- Ashley AldridgeAnn Arbor$298K
- Derek SusallaRochester Hills$242K
- Gabrielle DamoreRoyal Oak$200K
- Melissa MickelsonKalamazoo$168K
- Patrick CooneyNew Baltimore$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.